Aubry Aurélien, Francois Catherine, Demey Baptiste, Louchet-Ducoroy Marie, Pannier Christine, Segard Christine, Brochot Etienne, Castelain Sandrine
Laboratoire de Virologie, Centre Hospitalier Universitaire Amiens Picardie, 80054 Amiens, France.
UR 4294, Agents Infectieux, Résistance et Chimiothérapie (AGIR), Université de Picardie Jules Verne, 80000 Amiens, France.
Microorganisms. 2025 Mar 25;13(4):733. doi: 10.3390/microorganisms13040733.
(EBV) is one of the most prevalent human viruses worldwide. The COVID-19 pandemic, with its social distancing measures, has disrupted the circulation of many viruses. Delayed EBV primary infection is known to increase the risk of secondary conditions, including infectious mononucleosis, multiple sclerosis, and Hodgkin's lymphoma. In this context, we aimed to investigate whether EBV seroprevalence has been affected over time, particularly in relation to the COVID-19 period, by analyzing all patients admitted to Amiens University Hospital from January 2013 to December 2023 who underwent EBV serology. During this period, 19,771 EBV serologies were performed and analyzed. The total seropositive rate of EBV infections approached 90%, considering all non-negative serological profiles, with the rate stabilizing after 2017. The number of EBV serologies increased significantly until 2016, as well as the age of the screened patients. Less than 3% of patients remain seronegative after 25 years, indicating a seroprevalence of around 97%. The overall primary infection rate was 2.6%. There was no significant difference in the number of primary infections in 2020-2021, the years associated with confinements and curfews in France in the context of the COVID-19 pandemic, compared with the other years. The overall EBV seroprevalence and age of primary infection remained stable during the study period, suggesting a moderate impact of the COVID-19 pandemic on seroprevalence in this cohort.
爱泼斯坦-巴尔病毒（EBV）是全球最普遍的人类病毒之一。新冠疫情及其社交距离措施扰乱了许多病毒的传播。已知EBV初次感染延迟会增加继发疾病的风险，包括传染性单核细胞增多症、多发性硬化症和霍奇金淋巴瘤。在此背景下，我们旨在通过分析2013年1月至2023年12月入住亚眠大学医院并接受EBV血清学检测的所有患者，调查EBV血清阳性率是否随时间受到影响，特别是与新冠疫情期间的关系如何。在此期间，共进行并分析了19771次EBV血清学检测。考虑所有非阴性血清学结果，EBV感染的总血清阳性率接近90%，2017年后该比率趋于稳定。直到2016年，EBV血清学检测数量以及筛查患者的年龄均显著增加。25岁后血清阴性的患者不到3%，表明血清阳性率约为97%。总体初次感染率为2.6%。在新冠疫情期间法国实施封锁和宵禁的2020 - 2021年，初次感染的数量与其他年份相比没有显著差异。在研究期间，总体EBV血清阳性率和初次感染年龄保持稳定，表明新冠疫情对该队列的血清阳性率影响适中。
